GlaxoSmithKline Pakistan (KAR:GLAXO) Current Deferred Revenue: ₨0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAR:GLAXO GlaxoSmithKline Pakistan Ltd KAR:GLAXO
93 GF Score
Price ₨350.00
GF Value ₨323.39
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is GlaxoSmithKline Pakistan Current Deferred Revenue?

GlaxoSmithKline Pakistan KAR:GLAXO -0.27% 93 Current Deferred Revenue is ₨0 Mil as of Mar. 2026. GuruFocus rates KAR:GLAXO with a GF Score™ of 93/100 and a GF Value™ of ₨323.39 (Fairly Valued). The stock has 1 warning sign investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

GlaxoSmithKline Pakistan's current deferred revenue for the quarter that ended in Mar. 2026 was ₨0 Mil.

GlaxoSmithKline Pakistan Current Deferred Revenue Related Terms

GlaxoSmithKline Pakistan Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline Pakistan's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pakistan Current Deferred Revenue Chart

GlaxoSmithKline Pakistan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GlaxoSmithKline Pakistan Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
KAR:GLAXO
93GF Score
GlaxoSmithKline Pakistan Ltd KAR:GLAXO
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of ₨0 Mil mean?
GlaxoSmithKline Pakistan (KAR:GLAXO) has a Current Deferred Revenue of ₨0 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on GlaxoSmithKline Pakistan and its competitors.
Is GlaxoSmithKline Pakistan's Current Deferred Revenue too high?
GlaxoSmithKline Pakistan's current Current Deferred Revenue is ₨0 Mil. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's Current Deferred Revenue compare to ZTS and UTHR?
GlaxoSmithKline Pakistan's Current Deferred Revenue of ₨0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on GlaxoSmithKline Pakistan and its competitors. GlaxoSmithKline Pakistan's current Current Deferred Revenue is ₨0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₨323.39, compared to a current price of ₨350.00 — trading 8.2% above its estimated fair value. The current Current Deferred Revenue is ₨0 Mil. GlaxoSmithKline Pakistan's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current Current Deferred Revenue is ₨0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued. The current stock price of ₨350.00 is trading 8.2% above its estimated GF Value™ of ₨323.39. GuruFocus considers GlaxoSmithKline Pakistan to be Fairly Valued.

Key valuation signals for KAR:GLAXO:

  • Current Deferred Revenue: ₨0 Mil
  • GF Value™: ₨323.39 vs. price of ₨350.00 (8.2% above fair value)
  • GF Score™: 93/100 with 1 warning sign

No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GlaxoSmithKline Pakistan Business Description

Address 35, Dockyard Road, West Wharf, Karachi, PAK, 74000
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
93GF Score

Get the complete analysis for KAR:GLAXO

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨350.00
Price
₨323.39
GF Value